相关实验视频

Updated: Jul 9, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.0K

通过glofitamab成功治疗初级耐火DLBCL/HGBL - MYC/BCL2从FL转变:一个病例报告

Ming-Qiang Chu1,2,3,4, Ting-Juan Zhang1,2,3,4,5, Yuan Feng1,2,3,4

  • 1Department of Hematology, The Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.

Frontiers in immunology
|April 15, 2025
PubMed
概括

扩散型大B细胞淋巴瘤与MYC和BCL2重组 (DLBCL/HGBL-MYC/BCL2) 在标准治疗中表现不佳. 一名患有转变DLBCL/HGBL-MYC/BCL2的患者通过glofitamab实现了缓解,这表明其作为救援疗法的潜力.

关键词:
在 DLBCL/HGBL-MYC/BCL2 中.案例报告案例报告环球Fitamabb是什么意思主要耐火材料的第一耐火材料.转换的 转换的 转换的

更多相关视频

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

17.8K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.2K

相关概念视频

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...